Anti-VEGF Drugs Therapy for The Treatment of Wet AMD: A Review of Available Options and Recent Clinical Trials.
Purpose
This article aims to provide a comprehensive comparative analysis of anti-VEGF therapy in AMD, with a focus on the latest clinical evidence and guidelines, to discuss the mechanism of action of anti-VEGF drugs, review the latest clinical trials comparing the efficacy and safety of different anti-VEGF drugs.
Methods
A literature search was conducted using various databases including PubMed, Embase, and Cochrane Library. The search was limited to studies published in English language between January 2010 and September 2021.
Results
In summary, all three anti-VEGF drugs used in the treatment of wet AMD have been shown to be effective in improving visual acuity and reducing central retinal thickness. However, there are some differences between the drugs in terms of dosing, cost, and safety profiles. Bevacizumab is less expensive than ranibizumab and aflibercept but has been associated with a higher risk of ocular inflammation and endophthalmitis. Ranibizumab is an FDA-approved drug specifically developed for the treatment of wet AMD and has been extensively studied in clinical trials. Aflibercept is a newer drug with a longer half-life than ranibizumab and can be administered every 8 weeks.
Conclusion
In conclusion, while anti-VEGF therapy remains the current standard of care for wet AMD, alternative treatment options may be necessary for some patients who do not respond well to this therapy or experience adverse events. Clinicians should be aware of these alternative options and work with patients to develop a personalized treatment plan that optimizes outcomes and minimizes adverse events.
Conflict of interest
No
Authors 1
Last name
SHAIMERDENOVA
Initials of first name(s)
S.M.
Department
Vitreoretinal department
City
Karaganda
Country
Kazakhstan
This website uses cookies to ensure you get the best experience on our website.
Learn more